Mechanisms of fibrosis: therapeutic translation for fibrotic disease
Top Cited Papers
- 6 July 2012
- journal article
- review article
- Published by Springer Nature in Nature Medicine
- Vol. 18 (7), 1028-1040
- https://doi.org/10.1038/nm.2807
Abstract
Fibrosis is a key aspect of many chronic inflammatory diseases and can affect almost every tissue in the body. This review discusses recent advances in our understanding of the mechanisms of fibrosis, focusing on the innate and adaptive immune responses. It also describes how some of these crucial pathogenic pathways are being therapeutically targeted in the clinic. Fibrosis is a key aspect of many chronic inflammatory diseases and can affect almost every tissue in the body. This review discusses recent advances in our understanding of the mechanisms of fibrosis, focusing on the innate and adaptive immune responses. It also describes how some of these crucial pathogenic pathways are being therapeutically targeted in the clinic. Fibrosis is a pathological feature of most chronic inflammatory diseases. Fibrosis, or scarring, is defined by the accumulation of excess extracellular matrix components. If highly progressive, the fibrotic process eventually leads to organ malfunction and death. Fibrosis affects nearly every tissue in the body. Here we discuss how key components of the innate and adaptive immune response contribute to the pathogenesis of fibrosis. We also describe how cell-intrinsic changes in important structural cells can perpetuate the fibrotic response by regulating the differentiation, recruitment, proliferation and activation of extracellular matrix–producing myofibroblasts. Finally, we highlight some of the key mechanisms and pathways of fibrosis that are being targeted as potential therapies for a variety of important human diseases.Keywords
This publication has 180 references indexed in Scilit:
- Macitentan: entry-into-humans study with a new endothelin receptor antagonistEuropean Journal of Clinical Pharmacology, 2011
- Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: A novel mouse model for scleroderma?Arthritis & Rheumatism, 2011
- Lack of interleukin-1α or interleukin-1β inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic miceJournal of Hepatology, 2011
- Methylation determines fibroblast activation and fibrogenesis in the kidneyNature Medicine, 2010
- TGF-β activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTENNature Cell Biology, 2009
- The role of IL-1 in the pathogenesis of heart diseaseArchivum Immunologiae et Therapiae Experimentalis, 2009
- Cellular and molecular mechanisms of fibrosisThe Journal of Pathology, 2007
- Unique functions of the type II interleukin 4 receptor identified in mice lacking the interleukin 13 receptor α1 chainNature Immunology, 2007
- Macrophage-specific PPARγ controls alternative activation and improves insulin resistanceNature, 2007
- Monocyte and macrophage heterogeneityNature Reviews Immunology, 2005